FDA Stance On Antidepressant Warnings Unchanged By NIMH Suicide Findings
Executive Summary
A National Institute of Mental Health-funded study showing no increased risk of suicide with newer antidepressants does not change FDA's stance on the need for warnings about suicidality for the drug class
You may also be interested in...
Antipsychotic Risk Examined In NEJM; Did FDA Judge Atypicals Unfairly?
Conventional antipsychotic medications should not be prescribed as replacements for atypical products despite an FDA public health advisory about the newer agents because conventional medications appear to have higher mortality in elderly patients, an article in the Dec. 1 New England Journal of Medicine concludes
Antidepressant Long-Term Efficacy Pre-Approval Would Delay New Therapies
FDA's Psychopharmacologic Drugs Advisory Committee on Oct. 25 agreed with industry's key argument that the proposed requirement to complete long-term efficacy studies at the time of approval for major depressive disorder drugs would delay the entry of new therapies to market
FDA Adult Antidepressant Suicidality Analysis Will Take At Least A Year
FDA expects its assessment of data on suicidal thinking and behavior in adults on antidepressants will take at least a year to complete